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Although gentamicin is known to accumulate and persist in the kidneys after sys-
temic administration, its antibacterial activity at this site has not been determined.
In the present study the accumulation of gentamicin in rat kidneys before infection
prevented obstructive pyelonephritis due to Escherichia coli despite heavy urinary
tract infection in the obstructed pelvis; thus the kidneys were protected against in-
fection in the absence of effective levels of gentamicin in the urine. Stored gentamicin
also protected pyelonephritic rats from relapse after complete obstruction of the
kidneys. The level of antimicrobial activity of gentamicin in whole kidney tissue
was 95% less than that anticipated on the basis of levels measured after dilution of
kidney tissue homogenates; this low level of activity apparently was due in part to
high concentrations of solutes. In view of these results in rats, the possibility must
be considered that despite reduced activity, gentamicin storage might be useful in
the prophylaxis of kidney infection in patients with abnormalities of the urinary
tract. In the treatment of established kidney infection, the dose of gentamicin could
be reduced and the interval of its administration increased for minimal toxicity.
Accumulation and storage of gentamicin in the
kidneys has been reported recently [1] and de-
scribed in rats [2], dogs [3,4], rabbits [5], and nor-
mal human kidneys [3, 6-8]. These observations
dealing primarily with the nephrotoxicity of gen-
tamicin prompted the present study of (1) the
antibacterial activity of the stored drug and (2)
the possibility that its accumulation in the kid-
neys would prevent pyelonephritis if the drug
was given before bacterial infection and would
prevent relapse if the drug was given as thera-
py. These studies were done with a rat model of
retrograde Escherichia coli pyelonephritis. Re-
lapse was induced by obstruction of urinary flow
at different times after gentamicin therapy. Pre-
vention of relapse in rats receiving gentamicin
was compared with that in rats receiving ampi-
Received for publication March 13, 1978, and in revised
form Julv 6, 1978.
This work was supported by research grant no. 5ROI-
AI-12476-07 from the U.S. Public Health Service. by the
Franz Joseph Foundation, and by the American-Swiss Foun-
dation for Scientific Exchange.
Please address requests for reprints to Dr. M. P. Glauser,
Departement de Medecine, Centre Hospitalier Universi-
taire Vaudois, lOll Lausanne, Switzerland.
172
cillin, an antibiotic that does not accumulate in
the kidneys.
Materials and Methods
Bacteria. E. coli 06 (Williams), the strain
used to infect the rats, has been described pre-
viously [9]. It is inhibited by 2.5 p,g of ampicillin/
ml or by 1.2 p,g of gentamicinyml.
Production of pyelonephritis. Retrograde py-
elonephritis was produced in male Wistar-Lewis
rats weighing 225-250 g (Charles River Breed-
ing Laboratories, Wilmington, Mass.) as previ-
ously described [9]. In brief, after a suprapubic
incision was made, 103 E. coli organisms were
gently infused into the bladder until urine ap-
peared at the urethral meatus, whereupon the
inoculum consistently refluxed up the ureter. A
ligature was then tied loosely around the left
ureter with a silk suture through the left flank,
and the abdominal wall was closed. The liga-
ture was carefully removed from the outside 20
hr later. This procedure produces partial obstruc-
tion of urine flow and severe gross unilateral py-
elonephritis. Pyelonephritic kidneys are greatly
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enlarged and display numerous small abscesses
over the cortex that extend through the medulla
and riddle the interstitial areas with suppura-
tion [9].
Prophylactic administration of drug. Before
ligation, three groups of 24-36 rats each were
given im injections, each of which contained a
dose of 4 mg of gentamicin/kg of body weight in a
total volume of 0.1 ml. The injection schedules for
the three groups were as follows: (1) one injection
72 hr before ligation; (2) three injections, one
every 12 hr, with the last injection 72 hr before
ligation; and (3) seven injections, each at 12-hr in-
tervals, with the last injection given 12 hr before
ligation. The first two regimens allowed the study
of prophylaxis of pyelonephritis three days after
administration of gentamicin, while the third reg-
imen allowed the study of prophylaxis shortly
after administration of doses of gentamicin simi-
lar to those used in the treatment of pyelonephri-
tis (see below). A control group was given an im
injection of a O.l-ml volume of 0.9% NaCl in place
of each dose of gentamicin given to treated rats.
Sacrifice of rats. All treated and control animals
were killed with an overdose of ether 22 hr or
three days after ligation as specified in Results and
were bled from the heart. The abdominal wall was
opened, and the pelvic contents were aspirated
with tuberculin syringes. Kidneys were removed
aseptically, examined for gross evidence of pye-
lonephritis [9], and homogenized in I ml of 0.1 M
phosphate-buffered saline (PBS), pH 8.0; 0.5 ml
of the homogenate was used for bacteriological
study, and the remainder was stored at -20 C
until antibiotic levels were determined.
Prevention of relapse by renal accumulation
of gentamicin. We have shown in previous stud-
ies that as few as 46 live bacteria persisting after
treatment in the pyelonephritic kidney may
cause severe relapse when the ureter is reobstruct-
ed [10]. This phenomenon was used to determine
the level of antibacterial activity of stored genta-
micin given in the treatment of pyelonephritis.
For comparative purposes, pyelonephritic rats
were treated with ampicillin, an antibiotic that
does not accumulate in the kidney.
Treatment of groups of 20-24 rats was started
30 hr after ligation, when -75% of the rats had
severe kidney infection. In one group of rats,
sodium ampicillin (Bristol Laboratories, Syra-
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cuse, N.Y.) was given every 6 hr (160 mg/kg per
day). A second group received gentamicin (Scher-
ing, Kenilworth, N.].) at 12-hr intervals (8 mg/kg
per day). Each drug was injected im (alternating
thighs) in a volume of 0.1 ml. Treatment with
each antibiotic was continued for 3.5 days (am-
picillin given 14 times, gentamicin seven). As pre-
viously demonstrated, both of these dosages pre-
vented further progression of grossly evident
pyelonephritis while allowing a substantial de-
gree of infection to remain in the kidney [10].
Eight days or 12 hr after treatment was ended,
rats were either studied bacteriologically or li-
gated again to reestablish ureteral obstruction.
Rats that were religated were anesthetized with
ether, and a left paramedial incision into the
abdominal wall was made. The left kidney was
inspected for the presence of pyelonephritic cor-
tical lesions. The left ureter was then religated
with a silk ligature through the flank. The liga-
ture was left in place for 48 hr. Animals were
killed 24 hr after removal of the ligature (i.e.,
three days after religation) and examined for kid-
ney infection and pyelonephritis. Relapse of
pyelonephritis with severe recurrent infection
was determined by exacerbation of gross suppura-
tive lesions and by an increase in the number
of E. coli cultivated from the kidneys over the
number of E. coli found in kidneys of treated
control animals killed at time of religation. Only
animals exhibiting gross evidence of pyelonephri-
tis were evaluated since kidneys without gross evi-
dence were uniformly sterile.
Bacteriological cultures. The presence or ab-
sence of pyelonephritis was determined by mac-
roscopic examination of the kidneys and by the
culture of samples of kidney homogenates. Ten-
fold dilutions of a 0.5-ml aliquot of the homog-
enates were made in trypticase soy broth (Balti-
more Biological Laboratories [BBL], Cockeys-
ville, Md.), and 0.5 ml was plated onto trypti-
case soy agar. After the plates had been incu-
bated overnight aerobically at 37 C, the number
of cfu was counted. Cultures from animals treat-
ed with gentamicin were incubated in anaerobic
jars (Gasf'ak" catalyst; BBL) for 48 hr to decrease
the level of gentamicin activity [I I]. Urine sam-
ples obtained from the pelvis were cultured in
the same manner.
Determination of antibiotic levels. The level
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of gentamicin was assayed by the agar diffusion
method described by Sabath and Matsen [12]
with Bacillus subtilis ATCC 6633 (Difco Lab-
oratories, Detroit, Mich.). Bio-Assay steel plates
(Lab-Line Instruments, Melrose Park, Ill.)
were used as sample holders on the surface of the
agar plates, which contained 10 ml of antibiotic
medium 5 (Difco). Kidney homogenates were
assayed either without further dilution (undilut-
ed homogenates) or diluted I :50 in 0.1 M PBS,
pH 8.0 (diluted homogenates). Samples (0.05 ml)
were placed in the wells, allowed to diffuse over-
night at room temperature (about 21 C), and
then incubated for 2-4 hr at 37 C. The zone of
inhibition was measured with a vernier caliper,
and the level of drug was determined by com-
parison with a standard curve of gentamicin
(gentamicin sulfate;. Schering) diluted in 0.1 M
PBS, pH 8.0. In some experiments, gentamicin
was diluted in homogenates of normal kidney tis-
sue. Ampicillin was assayed similarly, except that
Sarcina lutea ATCC 9341 (American Type CuI·
ture Collection, Rockville, Md.), antibiotic me-
dium 3 (Difco), and 0.1 M PBS, pH 7.4, were used.
Each specimen was assayed in duplicate.
Statistics. The number of du/g in relapsing
kidney tissue was compared with the number
in control tissue by Student's unpaired t-test.
Statistical comparison of the attack rates of acute
pyelonephritis in the prophylaxis experiments
and of the rates of relapse in the religation ex-
periments was performed by the X2 method with
Yates's correction.
Results
Prophylaxis of pyelonephritis. In a series of
prophylaxis experiments, the susceptibility of
rats to ascending obstructive pyelonephritis was
tested at various intervals following prophylactic
administration of different quantities of genta-
micin. There was no protection against pyelone-
phritis in rats infected 72 hr after a single injection
of gentamicin; 22 (79%) of 28 rats had ma-
croscopic evidence of pyelonephritis three days af-
ter infection, a proportion similar to that seen
among untreated control rats (13 [76%] of 17).
However, when antibiotic-treated rats were chal-
lenged with E. coli 72 hr after the last of three in-
jections of gentamicin, the proportion was lowered
to four (20%) of 20 (P < 0.05).
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Thus it appeared that three injections of gen-
tamicin were sufficient to prevent pyelonephri-
tis in some animals, even when serum levels of
gentamicin were not detectable. This effect
might have been due either to an accumulation
of antibiotic in the kidney or to the presence of a
sufficient amount of antibiotic in the urine to
destroy the infecting bacteria. To eliminate the
latter possibility, animals that received three in-
jections of gentamicin were killed and studied bac-
teriologically 22 hr after ligation (1-2 hr after re-
moval of the ureteral ligature). The pelvic fluid
was cloudy in eight of 10 rats and contained a
mean of 6.6 X 107 viable E. coli/m!. In the pre-
viously cited experiment, when rats were killed
three days after ligation, all of the protected ani-
mals had sterile pelvic urine. Thus it was evident
that there was not enough gentamicin in the pel-
vic urine during the phase of acute obstruction
to prevent the bacterial inoculum from reach-
ing the obstructed renal parenchyma. The in-
hibition of renal parenchymal infection three
days after ligation must have resulted from anti-
microbial activity effective at the level of the re-
nal parenchyma and not at that of the pelvic
urine.
Pyelonephritis was prevented in all eight
animals that were given seven injections of gen-
tamicin and were ligated 12 hr (rather than 72
hr) after the last injection. No lesions were found
in any of these animals.
Prevention of relapse by gentamicin accumu-
lation. It has been shown that antibiotic treat-
ment of ascending obstructive pyelonephritis for
3.5 days prevents the progression of acute pyelo-
nephritis while allowing a substantial number of
bacteria to survive in the renal parenchyma
[10]. Thus studies were conducted to examine
whether the accumulation of antibiotic in the
kidney, as was seen after gentamicin treatment,
influenced the potential pathogenicity of these
remaining bacteria when the ureter was religat-
ed.
Religation of the left ureter 12 hr after com-
pletion of therapy: bacteriologic study three
days later. When the left ureter was religated
12 hr after the last injection of antibiotic, none
of eight pyelonephritic rats treated with genta-
micin had a recurrence of gross lesions. The
mean number of viable bacteria ± SD recovered
from their kidneys (1.39 ± 0.86 X 105) had not
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increased significantly over that found in the kid-
neys of treated controls killed at the time of reli-
gation (2.43 ± 2.51 X 104) .
In contrast, when pyelonephritic rats treated
with ampicillin were religated, eight of 10 devel-
oped recurrent destructive pyelonephritis in-
volving the entire kidney; the number of bac-
teria in the kidney increased significantly (from
1.16 ± 1.7 X 105 du to 1.57 ± 1.65 X 108 du; P <
0.01).
Evidently, in contrast to the ease with which
infection was reestablished in ampicillin-treated
animals, prior treatment with gentamicin pre-
vented the redevelopment of acute renal infec-
tion after ureteral ligation despite the persistence
of 105 viable bacteria in the obstructed kidneys.
This protection was impressive because we have
previously shown that under these experimental
conditions, as few as 46 live E. coli can cause se-
vere recurrent pyelonephritis in the absence of
accumulated antibiotic [10].
Religation of the left ureter eight days after
completion of therapy: bacteriologic study three
days later. When ureters were religated eight
days after completion of treatment with ampi-
cillin or gentamicin, there was no significant dif-
ference between the effect of ampicillin and that
of gentamicin on the incidence of relapse: eight
of 10 rats in the ampicillin-treated group and
nine of 17 rats in the gentamicin-treated group re-
lapsed. Eight days after treatment with either
drug, the kidneys of animals that experienced a
relapse contained significantly more bacteria than
the kidneys of treated control rats killed at the
time of religation (2.85 ± 4.51 X 107 du vs. 7.7 ±
7.0 X 102 du, P < 0.05 with gentamicin; 1.26 ±
175
1.02 X 108 du vs. 4.52 ± 1.10 X 104 cfu, P <
0.0025 with ampicillin).
Determination of antibiotic activity in kidneys.
No ampicillin activity was detected either 12 hr or
eight days after completion of therapy. Ih the
prophylaxis experiments (table 1), protection
against infection was a function of the level of
gentamicin activity measured in the undiluted
kidney homogenates. At 72 hr after the last of
three injections of gentamicin when only 20%
of the rats involved had acute pyelonephritis, a
level of activity equivalent to 1.26 f.Lg of genta-
micin/rnl was measured in the undiluted homo-
genates; this concentration is similar to the MIC
for the infecting strain of E. coli. At 72 hr after
a single injection of gentamicin, there was no pro-
tection against pyelonephritis, and the level of
activity in the undiluted kidney homogenates was
well below the MIC for the organism.
Similar relations between infection and the con-
centration of gentamicin in the undiluted homo-
genates were seen in the religation experiments
(table 1). The undiluted kidney homogenates
of rats that were protected from recurrent py-
elonephritis 12 hr after the last of seven injec-
tions of gentamicin contained a level of activity
equivalent to 4.33 f.Lg of gentamiciu/ml, a con-
centration three to four times the MIC for
the organism. Kidneys religated eight days after
treatment were not protected, and the level of ac-
tivity in the undiluted homogenates was equiva-
lent to 1.66 f.Lg of gentamicin1m!.
There is an obvious difference between the
prophylaxis and the religation studies in the rela-
tive effectiveness of the quantity of gentamicin
in the kidney and the drug's ability to prevent
Table 1. Activity of gentamicin in undiluted and diluted homogenates of kidneys from rats infected with Escherictua
coli 06 (Williams).
Time of sacrifice Gentamicin activity Percentage activity
after last injection (}.lgjml) in undiluted vs,
Experiment (no. of injections}" Undiluted Diluted diluted homogenate
Prophylaxis of pyelonephritis 72 (1) 0.41 ± 0.29 14.2 ± 7.2 2.9
72 (3) 1.26 ± 0.17 87.2 ± 24 1.44
12 (7) 8.4 ± 2.0 291 ± 109 2.9
Protection against recurrent
pyelonephritis 12 (7) 4.33 ± 1.3 203 ± 83 2.13
8 days (7) 1.66 ± 0.47 65 ± 19 2.55
NOTE. Data represent the mean value ± SD of determinations from eight to 16 rats. Each 1m injection contained gentamicin at a
concentration sufficient to give the rat a dose of 4 mg of gentamicin/kg of body weight in a volume of 0.1 ml.
'Time is given in hours unless indicated otherwise.
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infection. The conditions for initiation of infec-
tion in the two studies were sufficiently different
to make direct quantitative comparisons difficult.
Table 1 also shows that important differences
were observed when the level of gentamicin ac-
tivity in diluted renal homogenates was compared
with that in undiluted renal homogenates. The
experiments described in table 2 were designed to
investigate why the level of gentamicin activity in
the undiluted homogenates was lower than that
in diluted samples. Gentamicin (8 and 64 fLg/
ml) was added to undiluted homogenates of nor-
mal kidney tissue and to homogenates diluted
1:50 in 0.1 M PBS, pH 8.0. There was no signifi-
cant loss of activity in diluted homogenates.
However, activity was reduced in undiluted kid-
ney homogenates to the same degree as in the
kidneys of gentamicin-treated rats. A 1:50 dilu-
tion of the undiluted normal kidney homogenates
containing 8 or 64 fLg of gentamicin restored full
activity of gentamicin.
The pH of the undiluted kidney homogenates
was repeatedly measured as 7.2; that of the di-
luted homogenates, 8.0. When the kidney homo-
genates were diluted in buffer at pH 7.2 (table
2), the level of activity of gentamicin was lower
than at pH 8.0 but was reduced less than in
undiluted kidney homogenates. Thus while the
difference in activity can be explained to some
extent by differences in pH, the solute concen-
tration in the kidney homogenate evidently is
also an important factor in determination of the
biologic activity of gentamicin.
To see whether pyelonephritis had an influ-
ence on the renal accumulation and persistence
of gentamicin, the level of gentamicin activity
after 3.5 days of treatment was measured in ho-
mogenates of right kidneys and compared with
that found in homogenates of left kidneys. When
rats were killed 12 hr after the last injection of
Glauser, Lyons, and Braude
gentamicin, the mean level of activity (± so) in
the undiluted homogenates was 4.33 ± 1.3 fLg of
gentamicin/ml in the left kidney, compared with
8.4 ± 2.0 fLg/ml in the right kidney (P < 0.01).
Similarly, in diluted homogenates, the level of
gentamicin activity was 203 ± 83 fLg/ml in the
left kidney, compared with 291 ± 109 fLg/ml in
the right kidney (P < 0.0025). No such differ-
ence was seen when animals were killed eight
days after completion of therapy. This difference
might be related to the observation that genta-
micin, like other antibiotics, is inactivated by pus
in vitro [13]. Pyelonephritic left kidneys 12 hr
after completion of therapy showed large areas
of suppuration, but when rats were killed eight
days thereafter, the kidneys displayed mainly re-
tracted scars.
Discussion
This study of the pyelonephritic rat showed that
when gentamicin accumulated and persisted in
the kidney, it retained effective though reduced
antimicrobial activity at that site. However, a
significant discrepancy between the level of an-
tibacterial activity in vivo and the level of total
antibiotic activity in vitro, as measured in di-
luted kidney homogenates, was demonstrated.
This finding was not surprising because of the
following three points: (1) gentamicin activity
depends on electrolyte concentration and on os-
molality [14, 15]. Minuth et al. [16] showed that
the drug was much less active in human urine or
at osmolalities simulating concentrated urines.
Gentamicin activity should be reduced in the
renal medulla because solute concentration there
is similar to that in urine. (2) Kunin [17] found
a 90% reduction in level of activity of gentami-
cin when the drug was incubated in kidney ho-
mogenate and explained this reduction by tissue
Table 2. Effect of dilution and pH on the activity of gentamicin in homogenates of kidneys from uninfected rats.
Activity of ~entamicin (ILg{ml) incubated
in homogenates of normal kidney tissue
Activity of gentamicin (ILg{ml)
incubated in buffer solutionAmount ofgentamicin
added (ILg{ml)
64
8
Undiluted, pH 7.2
Diluted After 1:50
1:50, pH 8.0 Initial dilution
52 1.89 58.7
9.7 0.212 7.5
pH8.0
64
8.0
pH 7.2
14.0
0.61
NOTE. The data represent the mean value of measurements for five different samples.
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binding of gentamicin. We also found a reduc-
tion in the drug's level of activity when it was
incubated with undiluted kidney homogenate,
but this reduction was reversible because most of
the activity was recovered by dilution (table 2).
(3) The level of gentamicin activity demonstra-
ble in pyelonephritic left kidneys 12 hr after com-
pletion of therapy was slightly but significantly
lower than that in the intact right kidney. This
difference, which might be due to inactivation of
gentamicin by pus [13], was absent eight days after
therapy when suppuration was almost over.
Protection against pyelonephritis was observed
despite the presence of 107-108 bacteria/rnl in
pelvic urine and in the presence of obstruction.
Both Stamey et al. [18] and McCabe and Jackson
[19] have shown that to sterilize the urine of in-
fected patients with kidney involvement, it is
sufficient that antimicrobial drugs reach adequate
urinary concentrations. The experiments pre-
sented here show that gentamicin persisting in
the kidney prevents obstructive pyelonephritis
even if there is not enough antimicrobial activi-
ty in the urine to abolish heavy pelvic infection.
These observations of the rat model suggest
that despite an apparent reduction of activity
in vivo, the accumulation and persistence of gen-
tamicin in the kidneys might be used to advan-
tage. It is possible that dosages of gentamicin cur-
rently recommended for the treatment of pyelo-
nephritis in humans could be reduced, thereby
diminishing the risk of toxicity while maintain-
ing therapeutic effectiveness. Furthermore, it is
interesting to speculate that in small doses gen-
tamicin might be a useful means of preventing
kidney involvement in patients with persistent
urinary tract infections, especially in cases of ir-
reparable urinary tract abnormalities.
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